Vaxcyte's Rally: A Sign of Undervalued Potential or a Temporary Bounce?
Vaxcyte's shares have surged over 23% in the past month, sparking debate among investors. While a discounted cash flow model suggests significant upside, traditional metrics paint a more cautious picture. We examine the numbers and the narratives driving this biotech stock.